The past few weeks have been hard on many traders. Most are looking at a sea of red in their portfolios. This happens when you invest. Markets go up. Markets go down. But there are still plenty of opportunities on the OTC Markets. 4 OTC penny stocks to watch are American Battery Metals (OTCMKTS: ABML), Alpine 4 Holdings (OTCMKTS: ALPP), Greater Cannabis Company (OTCMKTS: GCAN), and Sunshine Biopharma (OTCMKTS: SBFM).
HOW TO TRADE OTC PENNY STOCKS
First up, it’s important to understand that trading OTC penny stocks are not the same as trading blue chips. OTC stocks are subject to enormous volatility like what we have witnessed over the past week or so.
This is why we have preached over and over again on our Insider Financial YouTube channel to book profits along the way. We warned our subscribers to not get greedy or get caught up in the diamond hands/paper hands BS.
PLAN OF ACTION
There are two choices for investors right now because selling is not an option.
One, investors can do their homework and look for OTC penny stocks that haven’t run yet. This is what we do at Insider Financial. We scan through hundreds of OTC penny stocks each week looking for the best alerts for our subscribers.
We preach the key to trading OTC stocks is finding momentum BEFORE it happens and then be patient. Now, when we say that we find momentum BEFORE it happens, we are investors looking to position our subscribers BEFORE the move happens.
We got our subscribers in early on TSNPD, which you can read our first article here, and ALPP, which you can read about here. his is where the big money is made and why so many of our subscribers are sitting on gains of over 5166% in ALPP and over 12,862% in TSNPD.
It’s also best to own a portfolio of quality OTC stocks. For some that can be as many as 10 to 20 or more OTC penny stocks.
We always alert our subscribers first before we publish for our regular readers. This is the value of having a subscription to Insider Financial, which you can sign up for here. We alert our subscribers with our best ideas before our regular readers.
The second move for OTC penny stock investors is to look for OTC penny stocks that were runners before and present dip-buying opportunities.
What do we mean by this?
The foundation of a great fortune is built during bear markets when there is blood in the streets. This selloff is when you want to be putting cash to work by buying quality OTC stocks. These are OTC stocks that were runners in the past and will run to new highs again.
YOU MUST LEARN TO EARN!
We try to help as much as we can, but in the end, it’s all up to you. You are running your own trading business.
Investing is not a team sport.
The purpose of what we do here at Insider Financial is not only to find winning alerts but also to teach. But we are just one resource. There are other resources as well.
For instance, if you want to day trade, we recommend the folks at True Trading Group, which you can check out their live streams here. They have a chat room as well as a ton of educational resources for their members.
The one negative about True Trading Group is that they don’t cover OTC stocks much. However, the good news is that we specialize in OTC stocks here at Insider Financial. In this article, we take a look at 4 OTC penny stocks ABML, ALPP, GCAN, and SBFM to find out what’s behind the move and our outlook for each.
OTC Penny Stocks ABML
We recommended ABML to our subscribers last year when ABML was just $.06 a share, which you can read here. Subscribers are still sitting on gains of 3483% even after the recent hit piece from the shorts.
We see ABML as a buy-the-dip opportunity thanks to the hit piece from short-and-distort Spruce Point. Of course, Seeking Alpha had to pick up the report and run it as “breaking news.”
The good news is that ABML is not taking the attacks lying down. The company issued a press release stating:
ABTC intends to defend itself vigorously against these false allegations and is reviewing all legal options at its disposal to hold the author(s) and sponsor(s) of these ‘reports’ and videos responsible for the baseless attacks. ABTC is in the process of hiring a nationally recognized law firm to investigate this matter and take all available legal recourse to protect our shareholders. Of course, the Company categorically denies the allegations. Responses to the material inaccuracies identified in the report are below. The personal attacks on Company executives and officers made by the short sellers are neither material nor factual but are a defamatory distraction from the Company’s achievements and progress.
We see ABML as having enormous potential. The company’s proprietary extraction and recycling processes will produce battery-grade lithium and nickel that can be sold directly to cathode manufacturers to tackle the growing consumer demand for EVs, cell phones, personal computers, and electronics such as power tools – that use lithium battery technology as power sources. Once the company opens its first-of-kind lithium battery recycling pilot plant in Fernley, we are going to see an epic short squeeze.
OTC Penny Stocks ALPP
Like ABML, ALPP is under attack from the shorts. This time, it’s another anonymous short-seller that goes behind the name Grizzly Research. Also like ABML, the so-called news site Seeking Alpha had to run the story as “breaking news.”
Folks, this is just one author’s opinion and they are talking their book with the hopes of scaring nervous longs into selling so that they can buy back the shares they shorted at a lower price. This is called short-and-distort. Unfortunately, this is all too common on the OTC Markets.
Alpine 4 CEO Kent Wilson disputed Grizzly’s claims. Wilson said that the idea IA and VAYU have had no operations is “just absurd” and that the report is a “hack job with a blatant attempt to short our stock.”
ALPP just raised $50 million as it prepares to uplist to NASDAQ. ALPP is also cleaning up its balance sheet in preparation for this uplisting. ALPP just retired $12.8 million in both short and long-term debt in its first-round debt payoffs.
Here are a few reasons why you should ignore the shorts when it comes to ALPP.
- ALPP now has over 24,000 shareholders throughout Europe and a growing number of shareholders in Asia and beyond.
- ALPP forecasts $42 million to $55 million in revenues this year.
- NASDAQ bound
- ALPP is looking at acquisitions that can add $25 million to $40 million in annual revenue.
- A bet on ALPP is also a bet on founder and CEO Kent Wilson. He is an expert on DMAIC / Six Sigma and Lean proficiencies. These are the strategies Jack Welch used to build GE.
OTC Penny Stocks GCAN
GCAN is making moves after uplisting to an OTCQB. To qualify for this market, companies must meet high financial standards, follow best practice corporate governance, demonstrate compliance with U.S. securities laws and be current in their disclosures.
Back in January, GCAN retired its remaining convertible debt. For those that know pennies, retiring convertible debt is always huge news and leads to huge moves.
What we like most about GCAN is that it’s one of the cheapest quality cannabis plays for investors with a market cap of just $7 million. We don’t see GCAN as being this cheap for much longer.
OTC Penny Stocks SBFM
We told our subscribers about SBFM back in January before its run to $.30 a share. SBFM looks set to make another run to new highs as smart investors bought the dip earlier this month. As we have said repeatedly, if you miss the initial move, wait and buy the dips!
SBFM is a play we like as there’s big money behind the company. SBFM has a $2 million financing package with RB Capital Partners Inc. SBFM is putting this money towards its ongoing development of the Company’s Coronavirus Treatment on a priority basis and the clinical development of Adva-27a, the Company’s flagship anti-cancer compound targeted for pancreatic cancer.
In addition, to working on the development of a treatment for COVID-19 which is now in the transgenic mice testing phase, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug-Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells.
Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is the owner of all patents and intellectual property pertaining to Adva-27a.
SBFM is PINK Current and has applied to become a QB on the OTC Markets. The financiers behind SBFM are already planning to uplist to NASDAQ. With a current market cap of just $66 million, SBFM is a ground floor opportunity ahead of a major run.
As we keep saying, there are always opportunities in the markets and there are still winning OTC penny stocks to buy. Huge gains can be made in such a short amount of time.
If you like any of these OTC penny stocks and have missed the move, our best advice in these tough times is to be patient and throw bids in below the market. Buying dips and selling rips as swing trades remains the best strategy in these markets.
It’s also important to look for OTC penny stocks that have yet to run. There are plenty of opportunities out there and we look at hundreds of OTC stocks to buy each week trying to find the best alerts for our subscribers.
Remember, all it takes is one or two to become a winner and you’ve crushed the market indices for the year.
As always, good luck to all (except the shorts)!
WHEN INSIDER FINANCIAL HAS A STOCK ALERT, IT CAN PAY TO LISTEN. AFTER ALL, OUR FREE NEWSLETTER HAS FOUND MANY TRIPLE-DIGIT WINNERS FOR OUR SUBSCRIBERS. WE SPECIALIZE IN FINDING MOMENTUM BEFORE IT HAPPENS!
Disclosure: We have no position in any of the securities mentioned. We wrote this article ourselves and it expresses our own opinions. We are not receiving compensation for it. We have no business relationship with any company whose stock is mentioned in this article. Insider Financial is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This article is not a solicitation or recommendation to buy, sell, or hold securities. This article is meant for informational and educational purposes only and does not provide investment advice.